The peptide blend CJC-1295/GHRP 2 is a combination of the peptides CJC-1295 and GHRP 2.
The Similarities between CJC-1295 and GHRP-2
Although CJC-1295 and GHRP-2 are two completely different peptides complete with totally different molecular structures, they share several basic functional purposes that, when blended, enable them to act very well together.
In essence, CJC-1295 contains the ability to increase the level of secretions relating to growth from certain cellular receptors. Scientific study has determined that these receptors play a key role within an animal test subject’s growth axis; a complex system that results in the control and regulation of growth secretions for purposes of maintaining homeostasis throughout the subjects’ body. The reason CJC-1295 is able to function in the manner that it does is due to its ability to increase the peptide’s half-life by a phenomenally significant amount. Normally, the peptide’s half-life is less than seven minutes. However, with the expression of CJC-1295, that short half-life expands to a total of over seven days. This long lengthening of the half-life allows for a much longer window for secretions to occur, which in turn allows for an increase in secretions. This then leads to a host of beneficially positive functions within an animal test subject that are related to growth, repair, and metabolic efficiency. Some of the benefits that have been derived from research include:
- The growth of muscular tissue
- Decrease in body fat
- More efficient recovery from injury
- Strengthening of immune system
GHRP-2 shares a basic functionality with CJC-1295, in the sense that the secretagogue has the ability to promote growth secretions in animal test subjects. Specifically, scientific study has determined that GHRP-2’s facility is such that it can simultaneously hone in on the pituitary gland and stimulate its processes. This is significant to note because the pea-size gland found at the base of the brain essentially is the chief controller and regulator of the endocrine processes found within an animal test subject. The secretions that are expressed, in turn, heighten the production of these secretions, which in this case specifically lead to an increase of the type of protein synthesis related to the building and repair of muscle growth. At the same time, GHRP-2 has the capability to prohibit the peptide responsible for regulating the endocrine system from secreting. This blocks an animal test subject’s natural reaction to create a level of homeostasis within the body that would otherwise negate the GHRP-2’s growth-based effects.
What’s more, GHRP-2 compensates for the increase in the animal test subjects’ increased efficiency in protein synthesis by stimulating the release of ghrelin. This self-regulating peptide is chiefly expressed by the stomach and its main purpose is to create the sensation of hunger, thus creating an elevated desire to eat. This elevated craving, when acted upon, provides more energy for the animal test subject to convert, which in turn leads to further growth regarding muscular tissue.
Scientific study regarding GHRP-2’s functionality in relation to animal test subjects’ endocrine system has derived several potential benefits regarding the peptide. Some of these benefits mirror the benefits that CJC-1295 has to offer, such as the growth of muscular tissue. However, other benefits have been specifically linked to GHRP-2, including:
- Improvements in anti-inflammatory action
- Improved bone density
- Improved skin elasticity
- Enhanced liver defense
Because CJC-1295 and GHRP-2 have both shown great ability to increase expressions of energy that tie to the endocrine-based properties related to growth on animal test subjects, scientific research has determined that the two peptides can function efficiently when blended in conjunction.
Minimal Side Effects
It should be noted that although this blend of CJC-1295 and GHRP-2 have produced some impressive positive benefits according to scientific study on animal test subjects, a few negative side effects have been recorded at the same time, including fatigue, an increase in water retention, a decrease in insulin activity, and tingling and numbness in extremities.
Furthermore, it should be noted that all of the results relating to the use of CJC-1295 and GHRP-2 have been the result of painstaking scientific study and research based on animal test subjects. All of the findings relating to both peptides have been derived while they have been in the research phase, which is a place both peptides still currently reside. As such, any research that is related to the study of CJC-1295 and GHRP-2 should exclusively be held to the confines of a strictly controlled research environment, such as a medical research facility or a laboratory.
